http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20000062391-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-72 |
| filingDate | 1997-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20000062391-A |
| titleOfInvention | Farnesyl transferase inhibitors |
| abstract | The present invention relates to novel products of formula (1), methods for their preparation, pharmaceutical compositions containing them and their use for the manufacture of a medicament. In formula (1), Ar represents a substituted or condensed phenyl radical or a polycyclic or heterocyclic aromatic radical; R represents a radical of the formula-(CH 2 ) m -X 1- (CH 2 ) n -Z and X 1 represents a single bond, O, S; m = 0, 1; n = 0, 1, 2; The CH 2 radical may be substituted; Z is carboxy, COOR 6 , (R 6 = alkyl), CON (R 7 ) (R 8 ) (R 7 = hydrogen or alkyl) and R 8 = hydrogen, hydroxy, arylsulfonyl, heterocyclyl, optionally substituted Amino, optionally substituted alkyloxy, optionally substituted alkyl, amino, PO (OR 9 ) 2 (R 9 = hydrogen or alkyl), -NH-CO-T (T = hydrogen or optionally substituted alkyl), or At 2, R 1 and R 2 = hydrogen or halogen or alkyl, optionally substituted alkyloxy, alkylthio, alkyloxycarbonyl or R 1 and R 2 are in the ortho position relative to one another and optionally substituted 1 or 2 To form a heterocyclic compound containing 2 hetero atoms; R 3 and R 4 = hydrogen or halogen or alkyl, alkylene, alkyloxy, alkylthio, carboxy or alkyloxycarbonyl; R 5 = hydrogen, alkyl, alkylthio; X = O or S or -NH-, -CO- methylene, vinyldiyl, alkene-1,1-diyl or cycloalkane-1,1-diyl; And Y = O or S (optical isomers and salts of racemic forms and products of formula 1). The product of formula (1) is an inhibitor of farnesyl transferase that exhibits significant carcinoid and anti-leukemic properties. |
| priorityDate | 1996-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 695.